Latest News

We’re proud to share that MicroSigX Biotech Diagnostic Limited, a spin-off from The Chinese University of Hong Kong (CUHK), has been awarded funding under the prestigious RAISe+ Scheme by the Innovation and Technology Commission (ITC) of the Hong Kong government.We’re proud to share that MicroSigX Biotech Diagnostic Limited, a spin-off from The Chinese University of Hong Kong (CUHK), has been awarded funding under the prestigious RAISe+ Scheme by the Innovation and Technology Commission (ITC) of the Hong Kong government.

Inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis, is projected to rise by 150% in Hong Kong between 2014 and 2034, with healthcare costs expected to exceed HK$400 million annually, according to an epidemiological study jointly led by The Chinese University of Hong Kong (CUHK)’s Faculty of Medicine (CU Medicine) and the University of Calgary.


Following her personal journey in Video Clip 1, this second clip captures Prof. Siew Ng’s engaging exchange with the moderator at the Asia Summit on Global Health (ASGH) — where she shares her perspective on translating academic innovation into real-world healthcare solutions.


We’re proud to spotlight our co-founder Prof. Siew Ng, who shared her inspiring career journey at the Asia Summit on Global Health (ASGH) — an event that brought together over 2,900 participants from 42 countries and regions.


We are proud to share our CEO Rachel Fan was invited as a distinguished panelist and speaker at the inaugural Hong Kong International Medical Device Regulatory Forum, co-hosted by the Faculty of Medicine, The Chinese University of Hong Kong and the Department of Health, HKSAR.


We are excited to share that our plenary abstract presentation at Digestive Disease Week (DDW) 2025, delivered by CUHK research investigator Dr. Louis Ho Shing Lau, received overwhelming positive feedback and continuous enquiries from top researchers and clinicians worldwide. This recognition underscores the transformative potential of our microbiome-based diagnostic test, M3CRC.


At DDW 2025, MicroSigX presented updated interim results from its international multicenter study on M3CRC, a novel microbial gene marker test for colorectal cancer screening. The data continues to show high sensitivity and specificity in detecting advanced neoplasia, reinforcing M3CRC’s potential to transform non-invasive screening.


(San Diego, 4 May 2025) Today at Digestive Disease Week (DDW) 2025, MicroSigX unveiled pivotal clinical data from its multi-center study across nine centers in the Asia-Pacific region on M3CRC, a microbiome-based diagnostic panel for colorectal cancer screening.


We are thrilled to announce that our M3 bacterial gene-marker test has been recognized in the 2023 Joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society of Digestive Endoscopy (APSDE) clinical practice guidelines for diagnosing colorectal neoplasia, published in the British Medical Journal – Gut. This endorsement highlights M3CRC's exceptional sensitivity and reliability.


Congratulations to our co-founder, Professor Siew Ng, Croucher Professor in Medical Sciences at CUHK Medicine, Director of the Microbiota I-Center (MagIC), and New Cornerstone Investigator, on achieving another significant success!

We are thrilled to announce the promising early results from our groundbreaking multicenter study on colorectal cancer screening, which will be presented at Digestive Disease Week (DDW) 2025, from May 3-6, in San Diego, USA.


We are thrilled to announce the launch of MicroSigX, a groundbreaking biotech diagnostics company co-founded by Prof. Siew Ng and Prof. Francis Chan of the Faculty of Medicine, The Chinese University of Hong Kong.